Zhao Yan, Yan Hui-ping, Tan Yu-fen, Feng Xia, Liu Yan, Cui Dan, Ma Dong-mei, Li Wei-hua, Zhang Hai-ping
Central Laboratory, Beijing You'an Hospital, Capital University of Medical Sciences, Beijing 100069, China.
Zhonghua Gan Zang Bing Za Zhi. 2007 Apr;15(4):283-6.
To study the significance of anti-soluble liver antigen/liver-pancreas (anti-SLA/LP) in diagnosing and typing autoimmune hepatitis (AIH).
Six thousand patients with abnormal liver functions, who had their autoantibodies checked by immunofluorescent assay (IFA) and immune blotting assay, were reviewed retrospectively.
Of these 6000 patients with liver diseases, 84 were diagnosed AIH. Eighteen patients, 0.3% of the 6000, patients with abnormal liver functions, were SLA/LP antibody positive, of which 17 were with AIH-III [2/17 with AIH /primary biliary cirrhosis (PBC) overlap syndrome], and 1 with chronic hepatitis B. Sensitivity and specificity of SLA/LP antibody in diagnosing AIH were 20.2% and 99.7% respectively, and the positive prediction value was 94.44%. The antinuclear antibody (ANA) titer in the AIH-III group was significantly lower than that of the AIH-I group (P < 0.05). The age of patients with anti-SLA/LP was higher (58.8% were over 50 years old) than those without this antibody (52.2% were 30 to 50 years old). There were no significant differences between the type III and type I AIH regarding gender, age, abnormal degree of liver function, PTA, IgG, liver cirrhosis rates and response to immunosuppressive therapy.
Anti-SLA/LP is highly specific for diagnosing AIH. Comparing the clinical data of type III and type I AIH, we did not find significant differences between the two groups.
研究抗可溶性肝抗原/肝胰抗体(anti-SLA/LP)在自身免疫性肝炎(AIH)诊断及分型中的意义。
回顾性分析6000例肝功能异常且行免疫荧光法(IFA)及免疫印迹法检测自身抗体的患者。
在这6000例肝病患者中,84例被诊断为AIH。18例肝功能异常患者(占6000例的0.3%)SLA/LP抗体阳性,其中17例为AIH-III型[17例中有2例合并AIH/原发性胆汁性肝硬化(PBC)重叠综合征],1例为慢性乙型肝炎。SLA/LP抗体诊断AIH的敏感性和特异性分别为20.2%和99.7%,阳性预测值为94.44%。AIH-III组抗核抗体(ANA)滴度显著低于AIH-I组(P<0.05)。抗SLA/LP抗体阳性患者年龄较大(58.8%超过50岁),高于无该抗体患者(52.2%为30至50岁)。III型和I型AIH在性别、年龄、肝功能异常程度、凝血酶原活动度(PTA)、免疫球蛋白G(IgG)、肝硬化发生率及免疫抑制治疗反应方面无显著差异。
抗SLA/LP对AIH诊断具有高度特异性。比较III型和I型AIH的临床资料,两组间未发现显著差异。